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ABSTRACT
Multiple sclerosis (MS) is a CD4+ T cell-mediated autoimmune disease affecting the central nervous system. It
was largely accepted that Th1 cells driven by IL-12 were pathogenic T cells in human MS and experimental
autoimmune encephalomyelitis, an animal model of MS. Recent data have established that IL-17-producing
CD4+ T cells, driven by IL-23 and referred to as Th17 cells, play a pivotal role in the pathogenesis of EAE. A
combination of TGF-β and IL-6 induce Th17 cell lineage commitment via expression of transcription factor
RORγt. Th17 cells and induced Foxp3+ T regulatory cells are in reciprocal position in the T cell lineage commit-
ment governed by TGF-β and IL-6. The vitamin A metabolite retinoic acid is involved in this process via TGF-β
dependent induction of Foxp3. We have demonstrated that human Th17 cells could be identified as CCR2+
CCR5− memory CD4+ T cells. It is becoming clear that IL-23Th17 axis also plays an important role in the
pathogenesis of various human autoimmune diseases including MS. Additionally, accumulating evidences
raise a possibility that CCR2 on Th17 cells may be a therapeutic target in MS.
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INTRODUCTION
Naïve CD4+ T cells begin a process of differentiation
into effector T cells upon stimulation with specific an-
tigens.1 Th1 effector cells produce IFN-γ and TNF-α,
while Th2 effector cells produce IL-4, IL-5, and IL-13.2
Th1 differentiation requires IL-12 and the transcrip-
tion factors STAT4, STAT1, and T-bet.3,4 Th2 differen-
tiation requires IL-4 and the transcription factors
STAT6 and GATA3.5 Th1 cells command the cellular
immunity to clear intracellular pathogens, whereas
Th2 cells lead the humoral immunity to control para-
sitic infections. However, dysregulated responses of
effector T cells cause various immunopathological
conditions. Namely, Th1 cells are thought to be in-
volved in organ-specific autoimmune diseases, while
Th2 cells may play important roles in allergy.
Multiple sclerosis (MS) is a chronic inflammatory
disease affecting the central nervous system (CNS)
white matter.6 Activation of autoreactive CD4+ T cells
specific for myelin antigens and differentiation to Th1
effectors were thought to be crucial for the develop-
ment of this disease. This widely accepted theory
about pathology of MS was based on data from ex-
perimental autoimmune encephalomyelitis (EAE), a
rodent model of MS. However, the functional role of
Th1 cells in EAE has been reconsidered upon the dis-
covery of Th17 cells.
PARADIGM SHIFT FROM TH1 TO TH17
It was previously believed that Th1 cells were patho-
genic T cells in EAE because myelin-specific T cells
produced large amount of IFN-γ but not IL-4 upon re-
call response to an immunized myelin antigen.7 Since
IL-12 was essential for the development of Th1-
mediated immunity,8 blocking IL-12 signaling was ex-
pected to ameliorate EAE. IL-12 is a heterodimeric
cytokine composed of p35 and p40 subunit.9 Using IL-
12p40 and p35-deficient mice, however, it was shown
that p35-deficient mice were susceptible, but p40-
deficient mice were resistant to EAE.10 The puzzle re-
garding pathogenesis of IL-12Th1 response in EAE
was resolved in 2003 by Cua et al using IL-23p19-
deficient mice.11 IL-23 is a heterodimeric cytokine
that share IL-12p40 subunit with IL-12 and possess a
unique p19 subunit.9 They demonstrated that IL-23p
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Fig. 1 Regulation of helper T cel diferentiation. Naїve CD4＋ T cels dif-
ferentiate into four distinct T cel subsets such as Th1, Th2, Th17 and in-
duced T regulatory cels (iTreg) dependent on the cytokine milieu. It should 
be noted that the lineage commitment to either Th17 or iTreg cels is deter-
mined by IL-6 when naїve T cels are stimulated in the presence of TGF-β 
(reciprocal diferentiation).
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19 and IL-12p40, but not IL-12p35, were essential for
the development of EAE.
Researching the mechanism underlying the essen-
tial role of IL-23 has revealed that autoreactive CD4+
T cells producing IL-17 were not induced in IL-23-
deficient mice in EAE and collagen-induced arthritis
(CIA).12,13 IL-17 (IL-17A) is a member of IL-17 family
(IL-17A-F)14,15 and stimulates various types of cells,
such as epithelial cells, endothelial cells and fibro-
blasts to produce proinflammatory cytokines and
chemokines.16-18 Furthermore, Th17 cells activated in
the presence of IL-23 in vitro exhibited a higher ca-
pacity to transfer EAE than Th1 cells activated in the
presence of IL-12.12 These results demonstrate that
IL-23Th17 axis rather than IL-12Th1 axis is impor-
tant for the development of EAE and CIA.19,20
REGULATION OF TH17 DIFFERENTIATION
Various in vitro differentiation systems have con-
firmed that IL-17 producing T cells were a distinct li-
nage cells from Th1 or Th2 cells since differentiation
of IL-17 producing T cells was promoted with block-
ing IFN-γ or IL-4 signaling.21,22 Subsequently, it has
been shown that a combination of transforming
growth factor-β (TGF-b) and IL-6 induces differentia-
tion of Th17 cells very efficiently (Fig. 1).23-25 When
naïve CD4+ T cells are stimulated in the presence of
TGF-β, CD4+ Foxp3+ cells, but not IL-17-producing
cells, are induced. Addition of TGF-β and IL-6 to naïve
CD4+ T cells during the stimulation completely abro-
gates expression of Foxp3 and results in concomitant
expression of IL-17 from these T cells, suggesting
that reciprocal relationship between Th17 cells and
induced T regulatory (iTreg) cells.24 The vitamin A
metabolite retinoic acid is involved in this reciprocal
differentiation of iTreg and Th17 cells via TGF-β de-
pendent induction of Foxp3.26,27 The importance of
TGF-β and IL-6 in the differentiation of Th17 cells has
been further confirmed in vivo using IL-6 deficient
mice and mice expressing a dominant negative form
of the TGF-β receptor II.28,29 Although IL-23 plays no
apparent role in Th17 lineage commitment, it seems
to be required for promoting survival andor prolif-
eration of these cells in vivo.23,25 Furthermore, it has
been established that IL-21, which is produced prefer-
entially by Th17 but not Th1 cells, is important for
Th17 differentiation.29,30
CD4+ T cell lineage commitment is regulated by
specific transcription factors. Namely, Th1 differentia-
tion requires STAT1, STAT4, and T-bet, whereas
STAT6, c-maf, and GATA-3 act to promote Th2 cy-
tokine production.3-5 Regarding Th17 cell differentia-
tion, retinoic acid-related orphan nuclear receptor
(ROR)γt is the key transcription factor that orches-
trates the differentiation of Th17 cell lineage.31
RORγt-deficient CD4+ T cells produce no IL-17 in re-
sponse to TGF-β and IL-6. Ectopic expression of
RORγt induces transcription of IL-17 in naïve CD4+ T
cells. STAT3, activated by IL-6 or IL-23, is also an es-
sential transcription factor in Th17 cell differentiation
via regulating RORγt.32 In addition, Interferon regula-
tory factor 4 (IRF4), which has been recognized to be
essential for Th2 cell differentiation, is also involved
in the regulation of RORγt and differentiation of Th17
cells.33 Among other signaling pathways IL-2 signal-
ing via STAT5 and IL-27 signaling via STAT1 con-
strain Th17 cell development.34-37
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Fig. 2 Diferential expression of chemokine receptors in human helper T 
cel subsets. During the diferentiation process CD4＋ T cels acquire certain 
sets of chemokine receptors, which confer the distinct migratory features to 
Th1, Th2 and Th17 cels. Others and we have identified two diferent Th17 
populations as bearing CCR4＋ CCR6＋ and CCR2＋ CCR5－ cels, 
respectively. Although the relationship between these two diferent popula
tions are not fuly understood, these Th17 cels may play diferent roles in 
diverse inflammatory environments.
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HUMAN TH17 CELLS IN HEALTH AND DIS-
EASE
Establishment of Th17 cells as a novel Th subset in
mice advances studies of human Th17 cells. Others
and we have used similar methods to isolate human
Th17 cells from PBMC according to expression pat-
tern of chemokine receptors.38,39 During the differen-
tiation process CD4+ T cells acquire certain sets of
chemokine receptors, which enable the distinct posi-
tioning of Th1 and Th2 cells.40 Namely, Th1 cells
preferentially express CCR5 and CXCR3 whereas
Th2 cells express CCR4, CCR8, and CRTh2.41-43 It is
conceivable that Th17 cells may also possess unique
expression pattern of chemokine receptors. We have
revealed that CCR2+ CCR5− memory CD4+ T cells
produce a large amount of IL-17 and little IFN-γ,
whereas CCR2+ CCR5+ cells reciprocally produced an
enormous amount of IFN-γ but little IL-17. These re-
sults indicate that CCR2+ CCR5− memory CD4+ T
cells belong to Th17 lineage (Fig. 2). Another group
has identified another Th17 cells in PBMC as CCR4+
CCR6+ cells. Although the relationship between these
two different populations of Th17 cells should be
clarified in the future studies, these Th17 cells may
play different roles in diverse inflammatory environ-
ments. The unique chemokine receptor expression
pattern of Th17 cells is thought to provide a basis for
their recruitment in specialized inflammatory condi-
tions.
In vitro differentiation studies have shown that
IL-1β but not TGF-β together with IL-6 or IL-23 is re-
quired for differentiation of human Th17 cells and ex-
pression of RORC, human ortholog of mouse
RORγt.44-46 These results suggest that human and
mouse Th17 cells require distinct factors during dif-
ferentiation.
It is becoming clear that IL-23Th17 axis may play
an important role not only in the animal models but
also in human chronic inflammatory diseases. Tran-
scripts encoding IL-17, IL-23, RORC but not IL-12 are
upregulated in psoriatic lesions.45,47 IL-22, a Th17
cell-derived cytokine, is required for IL-23-induced
acanthosis, hyperplasia of the epidermis characteris-
tic of psoriatic lesions.48 Besides a human IL-1223
monoclonal antibody efficiently improves psoriasis
symptoms.49 Same as EAE, IL-23Th17 rather than
IL-12Th1 was important for animal models of the in-
flammatory bowel diseases (IBD).50-53 Furthermore,
in genome-wide analysis of single nucleotide poly-
morphisms, an uncommon coding variant of the gene
encoding the IL-23 receptor conferred strong protec-
tion against Crohn’s disease,54 suggesting the IL-23
signaling pathway as a therapeutic target in IBD.
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A PATHOGENIC ROLE OF TH17 CELLS IN
MS
Microarray analysis demonstrated that IL-17 tran-
script is upregulated in the MS lesion.55 Concentra-
tions of IL-17 and IL-8 in cerebrospinal fluid (CSF)
are significantly higher in MS than healthy sub-
jects.56 The levels of IL-23 expression in monocyte-
derived dendritic cells are higher in MS patients than
those in healthy controls.57 Furthermore, a recent
study has shown that memory T cells producing IL-17
and IL-22 infiltrate into MS lesions.58 These results
suggest that Th17 cells may play important roles in
the pathology of MS.
Although IFN-β is the most common therapy to re-
duce rate of relapses in MS, blockade of chemokine
signaling pathways are expected to be a new thera-
peutic approach. Among several chemokine-
chemokine receptor systems tested, CCL2 (or MCP-
1)-CCR2 pathway was consistently shown to be es-
sential for development of EAE.59-61 Concerning MS,
CCL2 is upregulated in MS lesions.62-64 Although
CCL2 levels are decreased in the CSF of MS pa-
tients,65,66 it is explained by the mechanism that
CCL2 in the CSF is consumed by the infiltrated T
cells.67 Furthermore, both IL-17 and IL-22 stimulate
human Blood-Brain-Barrier endothelial cells to pro-
duce CCL2 but not CCL5 which is the ligand of CCR
5.58 These results raise a possibility that CCL2-CCR2
signaling pathway might play an important role in mi-
gration of Th17 cells to MS lesions and that CCR2 on
human Th17 cells might serve as a therapeutic target
in MS.
CONCLUSION
By discovering Th17 cells it has been revealed that
these Th17 but not Th1 cells are the pathogenic T
cells in EAE. Both TGF-β and IL-6 are required for
differentiation of Th17 cells, while IL-23 seems to be
essential for survival or expansion of this subset in
vivo. The differentiation process is regulated by the
specific transcription factor RORγt. It is necessary to
reconstitute the pathological theory of MS as well as
EAE from standpoint of Th17 cells. According to ex-
pression pattern of chemokine receptors, we were
able to identify human Th17 cells in PBMC as CCR2+
CCR5− cells. Blockade of the CCL2-CCR2 signaling
pathway that guides Th17 cells to the CNS may be a
therapeutic strategy in MS.
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